Literature DB >> 2872231

Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes.

J A Smith, D Henry, J Ngui-Yen, A Castell, S Coderre.   

Abstract

The activities of cefotaxime (CTX) and desacetyl cefotaxime (des-CTX) were tested both singly and in combination against 173 anaerobic clinical isolates. The MIC of CTX for 50% of 60 Bacteroides fragilis isolates was 22.4 micrograms/ml in broth, compared with 47.4 micrograms/ml in agar. This reduced efficacy in agar was seen with all species tested and is in apparent conflict with reported clinical efficacy of the drug. Synergy between CTX and des-CTX was observed with 70 to 100% of the isolates, including 60% of all Bacteroides spp. tested. The susceptibility results in a synergy system correlated well with those noted in a broth-disk elution method incorporating 32 micrograms of CTX and 8 micrograms of des-CTX per ml. The correlation was poorer when the broth-disk method contained 16 micrograms of CTX and 8 micrograms of des-CTX per ml.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872231      PMCID: PMC268803          DOI: 10.1128/jcm.23.6.1104-1108.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  8 in total

1.  Methods of testing combined antibiotic bactericidal action and the significance of the results.

Authors:  L P GARROD; P M WATERWORTH
Journal:  J Clin Pathol       Date:  1962-07       Impact factor: 3.411

2.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

3.  Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria.

Authors:  T D Wilkins; T Thiel
Journal:  Antimicrob Agents Chemother       Date:  1973-03       Impact factor: 5.191

4.  Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function.

Authors:  J T Doluisio
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

5.  Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

6.  Levels of cefotaxime in body fluids and tissues: a review.

Authors:  W J Novick
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

7.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

8.  Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft-tissue infections.

Authors:  H H Stone; E S Morris; C E Geheber; L D Kolb; W E Dunlop
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct
  8 in total
  5 in total

Review 1.  Susceptibility testing of anaerobic bacteria: myth, magic, or method?

Authors:  H M Wexler
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients.

Authors:  Zoya Hojabri; Mohammad Ahangarzadeh Rezaee; Mohammad Reza Nahaei; Mohammad Hossein Soroush; Morteza Ghojazadeh; Tahereh Pirzadeh; Mostafa Davodi; Mona Ghazi; Reza Bigverdi; Omid Pajand; Mohammad Aghazadeh
Journal:  Adv Pharm Bull       Date:  2013-02-07

Review 4.  Cephalosporins--cefotaxime 10 years later, a major drug with continued use.

Authors:  H C Neu
Journal:  Infection       Date:  1991       Impact factor: 3.553

5.  The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.

Authors:  H R Devlin; L Boskovski
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.